Bezafibrate Rescues Mitochondrial Encephalopathy in Mice via Induction of Daily Torpor and Hypometabolic State.
Neurotherapeutics
; 19(3): 994-1006, 2022 04.
Article
in En
| MEDLINE
| ID: mdl-35334081
ABSTRACT
Leigh syndrome (LS) is one of the most common mitochondrial encephalopathy diseases in infants. To date, there is still an absence of effective therapy. Bezafibrate (BEZ), a pan-peroxisome proliferator-activated receptor (PPAR) agonist, ameliorates the phenotype of the mouse model of mitochondrial disease via an unclear mechanism. Here, we applied it to Ndufs4 knockout (KO) mice, a widely used LS animal model, to observe the therapeutic effects and metabolic changes associated with BEZ treatment to explore the therapeutic strategies for mitochondrial diseases. Administration of BEZ significantly enhances survival and attenuates disease progression in Ndufs4 KO mice. Decreased oxidative stress and stunted growth were also observed. As a PPAR agonist, we did not find mitochondrial biogenesis or enhanced metabolism upon BEZ treatment. On the contrary, mice with dietary BEZ showed daily torpor bouts and lower metabolic rates. We speculate that activating energy-saving metabolism in mice may be associated with the therapeutic effects of BEZ, but the exact mechanism of action requires further study.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bezafibrate
/
Mitochondrial Encephalomyopathies
/
Torpor
Limits:
Animals
Language:
En
Journal:
Neurotherapeutics
Journal subject:
NEUROLOGIA
Year:
2022
Document type:
Article
Affiliation country: